N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: A novel class of antitumor agents targeting the colchicine site on tubulin

European Journal of Medicinal Chemistry

Volumn 67, Issue , 2013, Pages 196-207

  Wang, Xiao Feng ^a,c   Wang, Sheng Biao ^a   Ohkoshi, Emika ^b   Wang, Li Ting ^b   Hamel, Ernest ^d   Qian, Keduo ^b   Morris Natschke, Susan L ^b   Lee, Kuo Hsiung ^b,e   Xie, Lan ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c LANZHOU GENERAL HOSPITAL   (China)

^d NATIONAL CANCER INSTITUTE   (United States)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Colchicine binding site; Cytotoxicity; N Aryl 6 methoxy 1,2,3,4 tetrahydroquinolines; Tubulin polymerization inhibitors

Indexed keywords

3 BROMO 5 (N (4 METHOXYPHENYL) N METHYLAMINO) N CYCLOPROPYLBENZAMIDE; 3 BROMO 5 (N (4 METHOXYPHENYL) N METHYLAMINO) N METHYLBENZAMIDE; 6 METHOXY 2 METHYL 3,4 DIHYDRO 2H 1,4 BIQUINOLINE; 6 METHOXY N (2' (N METHYL)AMINOQUINAZOL 4' YL) 1,2,3,4 TETRAHYDROQUINOLINE; 6 METHOXY N (2' METHYLQUINAZOL 4 YL) 1,2,3,4 TETRAHYDROQUINOLINE; ANTINEOPLASTIC AGENT; COLCHICINE; COMBRETASTATIN A4; N (2' CHLOROQUINAZOL 4' YL) 6 METHOXY 1,2,3,4 TETRAHYDROQUINOLINE; N (3 BROMO 5(N CYCLOPROPYL)CARBAMOYL)PHENYL 6 METHOXY 1,2,3,4 TETRAHYDROQUINOL; PACLITAXEL; PROPRANOLOL; QUINOLINE DERIVATIVE; SULFORHODAMINE B; TERFENADINE; TUBULIN; UNCLASSIFIED DRUG; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MICROTUBULE ASSEMBLY; MOLECULAR MODEL; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

BJGUNGDUBFAZJF-UHFFFAOYSA-N; CKJVPMVADPIXNN-UHFFFAOYSA-N; COLCHICINE BINDING SITE; CYTOTOXICITY; FDQUVMAKHZXEJX-UHFFFAOYSA-N; FDYCTHWQCNDDJL-UHFFFAOYSA-N; FTMZJCYHPDAWMW-UHFFFAOYSA-N; GZMJPFYDEOCCRA-UHFFFAOYSA-N; HHKPUUIFQNECJS-UHFFFAOYSA-N; HUKWJNYCEZDAFN-UHFFFAOYSA-N; HUZJMKBTGUFMFQ-UHFFFAOYSA-N; HYOBVXAUEHOWFL-UHFFFAOYSA-N; IGSCZPCABVOJSO-UHFFFAOYSA-N; JOQRIEZWVNWGML-UHFFFAOYSA-N; JRQKACCJXWRRCO-UHFFFAOYSA-N; JZGLPKGGBIDFME-UHFFFAOYSA-N; KFOXZZAYGWYTRQ-UHFFFAOYSA-N; N-ARYL-6-METHOXY-1,2,3,4-TETRAHYDROQUINOLINES; NVIYNSOOPAAJBH-UHFFFAOYSA-N; OCEFQUWNZIDEES-UHFFFAOYSA-N; ORBAISZLWSRHJS-UHFFFAOYSA-N; PJOIMWRREFTKKZ-UHFFFAOYSA-N; QZGXGAIVITUVSU-UHFFFAOYSA-N; SDVCOWGIPMODEC-UHFFFAOYSA-N; SXLFBMRIJWONFS-UHFFFAOYSA-N; TUBULIN POLYMERIZATION INHIBITORS; UOSMAUJRTJCCEL-UHFFFAOYSA-N; VQIAEEFDUGUMGV-UHFFFAOYSA-N; YVMCASKEHBSJQW-UHFFFAOYSA-N;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KB CELLS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; POLYMERIZATION; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 84882536698     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.06.041     Document Type: Article

References (26)

1. M.A. Jordan, L. Wilson, Microtubules as a target for anticancer drugs, Nat. Rev. Cancer 4 (2004) 253-265. (Pubitemid 38525281)
2. C. Dumontet, M.A. Jordan, Microtubule-binding agents: a dynamic field of cancer therapeutics, Nat. Rev. Drug Discov. 9 (2010) 790-803.
3. S. Sengupta, S.A. Thomas, Drug target interaction of tubulin-binding drugs in cancer therapy, Expert Rev. Anticancer Ther. 6 (2006) 1433-1447. (Pubitemid 44697168)
4. D.W. Siemann, The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents, Cancer Treat. Rev. 37 (2011) 63-74.
5. R.P. Mason, D. Zhao, L. Liu, L. Trawick, K.G. Pinney, A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment, Integr. Biol. 3 (2011) 375-387.
6. X.F. Wang, X.T. Tian, E. Ohkoshi, B.J. Qin, Y.N. Liu, P.C. Wu, H.Y. Hung, M.J. Hour, K. Qian, R. Huang, K.F. Bastow, W.P. Janzen, J. Jin, S.L. Morris- Natschke, K.H. Lee, L. Xie, Design and synthesis of diarylamines and diarylethers as cytotoxic antitumor agents, Bioorg. Med. Chem. Lett. 22 (2012) 6224-6228.
7. X.F. Wang, E. Ohkoshi, S.B. Wang, E. Hamel, K.F. Bastow, S.L. Morris-Natschke, K.H. Lee, L. Xie, Synthesis and biological evaluation of N-alkyl-N-(4-methoxyphenyl)pyridin-2-amines as a new class of tubulin polymerization inhibitors, Bioorg. Med. Chem. 21 (2013) 632-642.
8. J. Blagg, Structure eactivity relationships for in vitro and in vivo toxicity, in: W. Anthony (Ed.), Annual Reports in Medicinal Chemistry, vol. 41, Academic Press, 2006, pp. 353-368.
9. E.H. Kerns, L. Di, Metabolic stability, in: In Drug-like Properties: Concepts, Structure Design and Methods, Academic Press, San Diego, 2008, p. 151.
10. X. Mei, A.T. August, C. Wolf, Regioselective copper-catalyzed amination of chlorobenzoic acids: synthesis and solid-state structures of N-aryl anthranilic acid derivatives, J. Org. Chem. 71 (2006) 142-149. (Pubitemid 43128070)
11. T.A. Jensen, X. Liang, D. Tanner, N. Skjaerbaek, Rapid and efficient microwaveassisted synthesis of aryl aminobenzophenones using Pd-catalyzed amination, J. Org. Chem. 69 (2004) 4936-4947. (Pubitemid 39014048)
12. V. Onnis, M.T. Cocco, V. Lilliu, C. Congiu, Synthesis and evaluation of antitumor activity of ester and amide derivatives of 2-arylamino-6- trifluoromethyl-3-pyridinecarboxylic acids, Bioorg. Med. Chem. 16 (2008) 2367-2378. (Pubitemid 351380946)
13. A. Nose, T. Kudo, Reduction of heterocyclic compounds. II. Reduction of heterocyclic compounds with sodium borohydride-transition metal salt systems, Chem. Pharm. Bull. 32 (1984) 2421-2425.
14. M. Perez-Sayans, J.M. Somoza-Martin, F. Barros-Angueira, P.G. Diz, J.M. Rey, A. Garcia-Garcia, Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases, Cancer Lett. 295 (2010) 135-143.
15. H.Y. Hung, E. Ohkoshi, M. Goto, K.F. Bastow, K. Nakagawa-Goto, K.H. Lee, Antitumor agents. 293. Nontoxic dimethyl-4,4′-dimethoxy-5,6,5′, 6′-dime-thylenedioxylbiphenyl-2,2′-dicarboxylate (DDB) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs, J. Med. Chem. 55 (2012) 5413-5424.
16. L.V. Rubinstein, R.H. Shoemaker, R.M. Paull, S. Tosini, P. Skehan, D.A. Scudiero, A. Monks, M.R. Boyd, Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines, J. Natl. Cancer Inst. 82 (1990) 1113-1117.
17. R.B.G. Ravelli, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, M. Knossow, Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain, Nature 428 (2004) 198e202.
18. A. Dorleans, B. Gigant, R.B.G. Ravelli, P. Mailliet, V. Mikol, M. Knossow, Variations in the colchicine-binding domain provide insight into the structural switch of tubulin, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 13775-13779.
19. A. Gangjee, Y. Zhao, L. Lin, S. Raghavan, E.G. Roberts, A.L. Risinger, E. Hamel, S.L. Mooberry, Synthesis and discovery of water-soluble microtubule targeting agents that binding to the colchicine site on tubulin and circumvent Pgp medicated resistance, J. Med. Chem. 53 (2010) 8116-8128.
20. L.Q. Sun, L. Zhu, K. Qian, B. Qin, L. Huang, C.H. Chen, K.H. Lee, L. Xie, Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates, J. Med. Chem. 55 (2012) 7219-7229.
21. S.X. Cai, Small molecule vascular disrupting agents: potential new drugs for cancer treatment, Anti-Cancer Drugs 2 (2007) 79-101. (Pubitemid 46723154)
22. M.R. Boyd, Status of the NCI preclinical antitumor drug discovery screen, in: V.T. Devita, S. Hellman, S.A. Rosenberg (Eds.), Cancer: Principles and Practice of Oncology Updates, J. B. Lippincott, Philadelphia, 1989, pp. 1-12.
23. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Woiff, M. Gray-Goodrich, H. Campbell, J. Mayo, M. Boyd, Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines, J. Natl. Cancer Inst. 83 (1991) 757-766.
24. P. Houghton, R. Fang, I. Techatanawat, G. Steventon, P.J. Hylands, C.C. Lee, The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity, Methods 42 (2007) 377-387. (Pubitemid 46860387)
25. E. Hamel, Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin, Cell Biochem. Biophys. 38 (2003) 1-22.
26. C.M. Lin, H.H. Ho, G.R. Pettit, E. Hamel, Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin, Biochemistry 28 (1989) 6984-6991. (Pubitemid 19219888)